Pharmacogenetic Tests Market Size, Share, and Growth Forecast, 2026 – 2033

The global pharmacogenetic tests market size is likely to be valued at US$16.6 billion in 2026 and is expected to reach US$46.6 billion by 2033, growing at a CAGR of 15.9% during the forecast period from 2026 to 2033, driven by increasing integration of personalized medicine into routine clinical decision-making. According to the U.S. FDA (2024), multiple drug labels now include pharmacogenomic information to guide safer prescribing and reduce adverse drug reactions, supporting wider clinical adoption. The Clinical Pharmacogenetics Implementation Consortium (CPIC, updated 2023–2024) has strengthened evidence-based guidelines for gene–drug pairs such as anticoagulants and oncology therapies, improving treatment precision. Growth is supported by the European Medicines Agency (EMA, 2023), encouraging pharmacogenomic biomarker inclusion in drug development.

Driver - Advancements in Genomic Technologies and Next-Generation Sequencing

The market growth is strongly driven by rapid advancements in genomic technologies, particularly Next-Generation Sequencing (NGS). According to the U.S. National Human Genome Research Institute (NHGRI, 2024), the cost of sequencing a human genome has dropped to under US$1,000, enabling large-scale clinical adoption of pharmacogenomic testing.

These technologies allow faster, more accurate, and cost-effective analysis of gene variants linked to drug metabolism and response. Improved sequencing throughput and automation have increased laboratory efficiency, while integration of bioinformatics tools enhances the interpretation of complex genetic data. This is significantly accelerating adoption in precision medicine and routine clinical decision-making.

Next-generation sequencing is increasingly used across oncology, cardiology, and rare disease management for comprehensive genomic profiling. The National Institutes of Health (NIH, 2024) reports that over 70% of precision oncology trials in the U.S. now incorporate genomic biomarkers for treatment selection. It enables the identification of rare variants affecting drug efficacy and toxicity, improving patient-specific therapy outcomes.

Restraint - Limited Clinical Awareness and Standardization across Healthcare Systems

Many physicians lack adequate training in pharmacogenomics, leading to underutilization of available testing tools in routine clinical practice. Variability in guidelines and inconsistent integration of pharmacogenetic data into treatment protocols hinder widespread adoption. In several regions, genetic testing is still viewed as a specialized or research-focused tool rather than a standard clinical requirement.

Differences in regulatory frameworks, testing methodologies, and reimbursement policies create inconsistencies in adoption rates across countries. Limited interoperability between laboratory systems and electronic health records restricts seamless integration of pharmacogenomic data into clinical workflows. In developing regions, infrastructure constraints and high testing costs also reduce accessibility.

Opportunity - Expansion of Pharmacogenomics in Psychiatry and Neurology

The expansion of pharmacogenomics in psychiatry and neurology presents a strong growth opportunity. According to the World Health Organization (WHO, 2024), nearly one in eight people globally live with a mental disorder, significantly increasing demand for personalized psychiatric treatment. Pharmacogenetic testing helps address high variability in response to antidepressants and antipsychotics by enabling gene-guided drug selection and dosing.

This reduces trial-and-error prescribing, improves treatment response rates, and enhances patient safety. Rising awareness among clinicians and integration of pharmacogenomic guidelines into psychiatric care are accelerating adoption across developed healthcare systems.

In neurology, pharmacogenetic testing is gaining importance in managing conditions such as epilepsy, Alzheimer’s disease, and Parkinson’s disease, where drug response variability is high. The National Institute of Neurological Disorders and Stroke (NINDS, 2023) highlights that nearly 30% of epilepsy patients experience inadequate response to first-line anti-seizure medications, reinforcing the need for genetically guided therapy.

Product Type Insights

Single gene tests are expected to lead the pharmacogenetic tests market, accounting for approximately 60% of revenue in 2026, driven by their established clinical utility, lower cost, and easy interpretation of gene–drug interactions. These tests are widely used in routine clinical practice, especially for identifying CYP450 enzyme variants that influence drug metabolism. For example, CYP2C19 testing is commonly used to guide clopidogrel therapy in cardiology patients, ensuring effective platelet inhibition and reducing cardiovascular risks. Their strong integration into hospital workflows and reimbursement coverage supports widespread adoption.

Whole genome sequencing & next-generation sequencing (NGS) is likely to represent the fastest-growing segment, supported by its ability to analyze multiple genes simultaneously and provide comprehensive genomic insights. Its adoption is increasing rapidly due to declining sequencing costs and expanding clinical applications. For instance, NGS-based panels are increasingly used in oncology to identify multiple drug-targetable mutations in cancer patients, enabling highly personalized treatment strategies.

Therapeutic Area Insights

Oncology is projected to lead the market, capturing around 40% of the revenue share in 2026, supported by its strong reliance on companion diagnostics and targeted therapy selection. Pharmacogenetic testing plays a critical role in identifying tumor-specific genetic mutations that influence drug response and toxicity. A notable example includes EGFR mutation testing in non-small cell lung cancer, which helps clinicians select appropriate targeted therapies such as tyrosine kinase inhibitors, significantly improving patient outcomes.

The neurology segment is likely to be the fastest-growing therapeutic area, driven by increasing use of genetic testing in managing psychiatric and neurological disorders. Pharmacogenomics is widely applied in selecting antidepressants and antiepileptic drugs to improve treatment response and reduce adverse effects. For instance, genetic testing for CYP2D6 variants is increasingly used to guide antidepressant dosing in patients with depression, improving therapeutic outcomes.

North America Pharmacogenetic Tests Market Trends

North America is anticipated to be the leading region, accounting for a market share of 48% in 2026, driven by advanced healthcare infrastructure, strong regulatory support, and rapid adoption of precision medicine. The region benefits from high integration of pharmacogenomic data into clinical workflows and widespread use of companion diagnostics in oncology and cardiology. For example, Quest Diagnostics has expanded its pharmacogenomic testing portfolio to support personalized drug therapy selection, particularly in mental health and cardiovascular care.

U.S. Pharmacogenetic Tests Market Trends

The U.S. dominates the regional market, driven by strong FDA support for pharmacogenomic labeling and increasing adoption of precision medicine initiatives such as the All of Us Research Program. Major hospitals are integrating genetic testing into routine care, especially for oncology and psychiatry. The rising prevalence of chronic diseases and mental health disorders is increasing demand for personalized therapies.

Canada Pharmacogenetic Tests Market Trends

Canada is a significant market for pharmacogenetic tests supported by government-backed genomics initiatives such as Genome Canada and the increasing adoption of pharmacogenomic-guided therapy in oncology care. Canadian healthcare systems are focusing on reducing adverse drug reactions through genetic screening programs in hospitals. Provincial healthcare reforms are improving access to personalized medicine, particularly in cancer treatment centers.

Europe Pharmacogenetic Tests Market Trends

Europe is likely to be a significant market for pharmacogenetic tests, due to regulatory harmonization, increasing adoption of precision medicine, and strong clinical research networks. The region benefits from EU-funded genomic initiatives and the rising integration of pharmacogenomic testing in oncology and neurology care pathways. For example, Roche has expanded its companion diagnostic solutions across Europe to support targeted cancer therapies, improving treatment selection and patient outcomes.

U.K. Pharmacogenetic Tests Market Trends

The U.K. is a significant market for pharmacogenetic tests, supported by the National Health Service (NHS) genomics program, which integrates genetic testing into routine healthcare delivery. The U.K. is expanding pharmacogenomic applications in mental health treatment to improve antidepressant response rates. The U.K. Biobank continues to support large-scale pharmacogenomic research, enabling a better understanding of gene-drug interactions.

Germany Pharmacogenetic Tests Market Trends

Germany dominates the regional market, driven by advanced healthcare infrastructure and a strong focus on clinical research in genomics and personalized medicine. German hospitals are increasingly adopting pharmacogenetic testing for oncology and cardiology to improve drug safety and efficacy. The country’s robust biotech ecosystem and government support for digital health innovation are accelerating adoption.

Asia Pacific Pharmacogenetic Tests Market Trends

The Asia Pacific region is likely to be the fastest-growing region, driven by expanding healthcare infrastructure, a large population base, and increasing government investment in precision medicine. The region is witnessing the rapid adoption of genomic technologies in clinical practice, especially in oncology and neurology. For instance, Fulgent Genetics has expanded its genetic testing services in Asia to support oncology-focused pharmacogenomic screening, improving treatment personalization and accessibility.

China Pharmacogenetic Tests Market Trends

China dominates the regional market, driven by strong government support through national precision medicine programs and large-scale genomic initiatives. The country is investing heavily in biotechnology infrastructure and hospital-based genetic testing facilities. Increasing collaboration between domestic biotech firms and companies is accelerating the adoption of pharmacogenomic testing in oncology care. Rising demand for targeted cancer therapies is a key growth driver across major hospitals.

India Pharmacogenetic Tests Market Trends

India is a significant market for pharmacogenetic tests, supported by increasing healthcare awareness, rising burden of chronic diseases, and government-supported genomic research initiatives such as GenomeIndia. The country is gradually integrating pharmacogenomic testing into oncology and psychiatric care. Expanding diagnostic laboratory networks and declining sequencing costs are improving accessibility.

The global pharmacogenetic tests market exhibits a moderately fragmented structure, driven by the presence of both large multinational diagnostics companies and specialized genomic testing firms. While a few dominant players hold a significant share, a wide base of regional laboratories and niche service providers contributes to competitive diversity.

With key leaders, including Thermo Fisher Scientific, Illumina, F. Hoffmann-La Roche, and Quest Diagnostics, the market is characterized by strong technological capabilities and distribution networks. These companies maintain leadership through continuous investment in genomic technologies, expanding test portfolios, and leveraging clinical evidence to strengthen their market position.

Key Industry Developments:

• In May 2026, Foundation Medicine announced the launch of its new pharmacogenetic test, FoundationOne® PGx, developed in partnership with Fulgent Genetics, aimed at improving cancer care by identifying genetic variations that influence drug metabolism and enabling more personalized therapy selection while reducing adverse drug reactions.
• In February 2026, Thermo Fisher Scientific announced the launch of its TacroType™ pharmacogenetic test, a laboratory-developed solution designed to help transplant patients receive optimized dosing of the anti-rejection drug tacrolimus by analyzing CYP3A5 genetic variations, enabling more personalized treatment and reducing trial-and-error dosing in critical post-transplant care.
• In September 2025, Quest Diagnostics launched an advanced pharmacogenomics (PGx) testing service developed with Coriell Life Sciences, designed to help clinicians personalize medication selection and dosing by analyzing 17 genes and 4 HLA alleles, enabling improved treatment outcomes and reducing adverse drug reactions across multiple therapeutic areas.